Charles River (CRL) Laboratories International and Deciphex announced the next phase of a strategic collaboration to focus on advancing cutting-edge image management solutions, while continuing to develop novel artificial intelligence (AI) tools for toxicologic pathology. Together, Deciphex and Charles River will deliver a fully integrated image management, distribution, and archiving workflow designed to maximize efficiency, precision, and scalability in pathology workflows.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River price target lowered to $184 from $220 at Morgan Stanley
- Charles River Labs: Hold Rating Amid Revised Revenue Forecasts and DCF Valuation
- CITES decision on Cambodia NHP ban positive for Charles River, says Evercore ISI
- Charles River price target lowered to $195 from $210 at BofA
- Charles River downgraded to Market Perform from Outperform at William Blair